Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (845)	10/19/1999 1:05:00 PM
From: JGoren	Read Replies (1) \| Respond to of 1906

All biotechs up big today. CNBC reports that Amgen subject to several favorable comments by analysts, but I haven't yet found press release on same. Report re Enbrel: Enbrel reported effective in stopping progression of rheumatoid arthritis in 75% of patients with early stages of the joint disease--patient trial. Enbrel is sold by Immunex and American Home Products Corp., which owns a majority stake in Immunex. Enbrel is reported to perform better than the generic drug methotrexate, now the "standard of care," the latter having only a 57% effective rate.